280Bio
China - ZZBiotechnology
Focus: 280Bio is a China-based biotechnology company focused on KRAS inhibitor development for oncology indications. The company is in early-stage development with a single Phase 1 program.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About 280Bio
AI assessmentNot HiringNo open roles listed right now. Follow 280Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
YL-13027
Metastatic Pancreatic CancerClinical Trials (1)
NCT06199466A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
Phase 1Help build intelligence for 280Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.